Ausio Pharmaceuticals
Stage
Incubator/Accelerator | AliveMissing: Ausio Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ausio Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Ausio Pharmaceuticals Patents
Ausio Pharmaceuticals has filed 4 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/25/2017 | 8/27/2019 | Synthetic estrogens, Alzheimer's disease, Phenols, Small nuclear RNA, Amines | Grant |
Application Date | 7/25/2017 |
|---|---|
Grant Date | 8/27/2019 |
Title | |
Related Topics | Synthetic estrogens, Alzheimer's disease, Phenols, Small nuclear RNA, Amines |
Status | Grant |
Latest Ausio Pharmaceuticals News
Dec 19, 2018
Estrogen Receptor Beta Partial Agonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Estrogen Receptor Beta Partial Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Estrogen Receptor Beta Partial Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. The report assesses the active Estrogen Receptor Beta Partial Agonist pipeline products by developmental stage, product type, molecule type, and administration route. Key Topics Covered:
Ausio Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Ausio Pharmaceuticals's headquarters?
Ausio Pharmaceuticals's headquarters is located at 1776 Mentor Avenue, Cincinnati.
What is Ausio Pharmaceuticals's latest funding round?
Ausio Pharmaceuticals's latest funding round is Incubator/Accelerator.
Who are the investors of Ausio Pharmaceuticals?
Investors of Ausio Pharmaceuticals include Hamilton County Business Center.
Who are Ausio Pharmaceuticals's competitors?
Competitors of Ausio Pharmaceuticals include Deciphera Pharmaceuticals, VentiRx Pharmaceuticals, Reata Pharmaceuticals, Bellicum Pharmaceuticals, Omthera Pharmaceuticals and 12 more.
Compare Ausio Pharmaceuticals to Competitors
Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease
KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.
Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders
Bluefish Pharmaceuticals offers a range of quality pharmaceuticals at prices that as many as possible will be able to afford.
Greystone Pharmaceuticals is a healthcare company focused on wound technologies.
Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.